The Most Favored Nation (MFN) Executive Order promises fairer drug prices, but it delivers the opposite - eroding the very U.S. ecosystem that develops new treatments. By pegging Medicare rebates to the cheapest global prices, MFN collapses revenue streams that pay for drug

MFN (Most Favored Nation) pricing aims to give American patients the lowest global drug rates, but our research started by asking a simple question: what happens when you tie U.S. Medicare rebates to the cheapest prices abroad? We adapted our recently completed Medicaid and

Tying US drug rebates to the lowest GDP-adjusted global rates strips America of its biopharma jobs and state budgets. Most Favored Nation pricing ties US drug rebates to the lowest GDP-adjusted price from a 33-country reference basket. We found that MFN pricing applied to

The Inflation Reduction Act's (IRA) pill penalty is reshaping oncology pipelines, as early-stage funding for high-Medicare-exposure therapies has dropped dramatically. Recently, Duane Schulthess spoke on an IQVIA panel at the 2025 Pre-ASCO Symposium to discuss how the IRA's Part

Patient advocacy groups and disease foundations hold a pivotal role in shaping legislative outcomes. As Robert Coughlin observed, delivering targeted briefings to legislators can bridge the gap between technical policy proposals and real‑world patient impact. In the context of

In our latest Vital Health Podcast, host Duane Schulthess is joined by Sam Rasty of Sensorium Therapeutics, Steve Potts (Steven Potts) at ICAN, International Cancer Advocacy Network, and Joseph Hammang, Ph.D., to explore how U.S. health policy is reshaping neuroscience innovation, investment priorities, and patient

The field of neuroscience is witnessing rapid advancements, driven by biotechnology and the use of AI and machine learning. Sensorium Therapeutics exemplifies this trend by focusing on the natural evolution of drug development. In our latest Vital Health Podcast, we had an

Recent legislative discussions have highlighted the pressing need for reforms regarding small-molecule drug development. Two key pieces of legislation, the EPIC Act and the ORPHAN Cures Act, are at the center of these discussions, aiming to address existing disparities in drug

On our latest Vital Health Podcast, we sit down with Steve Potts (Steven Potts; ICAN, International Cancer Advocacy Network), Joe Hammang, and Sam Rasty (Sensorium Therapeutics), to talk about why curing Alzheimer’s and rare conditions remains so challenging. They explain a proposed law called the EPIC Act, which

Our latest Vital Health Podcast brings together Sam Rasty (Sensorium Therapeutics), Steve Potts (Steven Potts, ICAN, International Cancer Advocacy Network), and Joe Hammang to explore how U.S. health policy influences biotech innovation and patient access. Key topics: - Inflation Reduction Act pricing controls and

Global drug innovation is migrating to China as U.S. policy stumbles: Our latest analysis shows that Most Favored Nation (MFN) reference pricing proposals risk accelerating the migration of US biopharma research to China - a trend reflected in record licensing partnerships with

Bringing a new therapy to market requires massive upfront investment, and to help recoup those R&D costs, drug developers get a temporary monopoly, known as a data exclusivity period, during which no generic drugs can enter. For small‑molecule pills, that window is only nine

The true worth of a medicine goes far beyond its upfront cost. When we only focus on list price, we ignore the downstream effects that innovative therapies deliver - from boosting workforce productivity and easing caregiver burdens to generating scientific breakthroughs that

Most Favored Nation (MFN) reference pricing would tie U.S. drug rebates to the lowest global rates, collapsing the very revenue streams that fund basic science, clinical trials, and manufacturing. Our analysis shows that, over the next decade, applying MFN to Medicare Parts B&D

The Inflation Reduction Act (IRA) was meant to ease patients’ drug bills by having Medicare negotiate prices with manufacturers and capping insulin copays. In reality, those negotiated savings are not reaching the people at the pharmacy counter. A new report by DLA Piper - led

In our latest Vital Health Podcast, host Duane Schulthess convenes three leading voices from the 2025 BIO International Convention - prominent physicians, innovators, and advocates shaping the future of drug development in the wake of the Inflation Reduction Act (IRA).

The Inflation Reduction Act (IRA) was implemented to rein in drug prices through Medicare negotiations. The promised result was affordable medicines. However, our data and on-the-ground feedback reveal an unintended consequence. Early-stage venture capital is shifting away from

Yesterday, the White House released a fact sheet outlining steps to bring American drug prices in line with the lowest global rates, including “calling on manufacturers to provide MFN prices to every single Medicaid patient” and “requiring manufacturers to stipulate that they

In our recent Vital Health Podcast, host Duane Schulthess sat with Barbara McAneny, Rafa Fonseca (Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽), and Steve Potts (Steven Potts) from the 2025 BIO International Convention to discuss the future of drug development in the wake of the Inflation Reduction Act (IRA).